Cyteir Therapeutics
Cyteir Therapeutics is a clinical-stage biotechnology company focused on developing innovative cancer therapies that target DNA damage response pathways. Leveraging expertise in synthetic lethality, Cyteir aims to create precision medicines that selectively target cancer cells while minimizing effects on healthy tissue. The company’s lead program centers on inhibiting key enzymes involved in DNA repair, offering potential new treatment options for patients with hematologic malignancies and solid tumors. Through a robust pipeline and commitment to scientific excellence, Cyteir Therapeutics strives to advance novel oncology solutions that address significant unmet medical needs and improve patient outcomes.
